Sp1285
EOSINOPHILIC ESOPHAGITIS: DISCOVER A TREATMENT OPTION FOR YOUR PATIENTS
Date
May 8, 2023
Society: DDW
Take an afternoon break with us to learn about a treatment option for your appropriate patient with eosinophilic esophagitis. An expert will walk us through long-term clinical data, an example of an appropriate patient, and answer your questions! Sponsored by Sanofi and Regeneron
Take an afternoon break with us to learn about a treatment option for your appropriate patient with eosinophilic esophagitis. An expert will walk us through long-term clinical data, an example of an appropriate patient, and answer your questions! Sponsored by Sanofi and Regeneron
Presenter
Tracks
Related Products
FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
Esophageal eosinophilic inflammation and remodeling lead to fibrostenosis in many patients with eosinophilic esophagitis (EoE)…
EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
